Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Expected to Post Quarterly Sales of $6.47 Million

Wall Street brokerages predict that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will report sales of $6.47 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Pieris Pharmaceuticals’ earnings. The highest sales estimate is $8.90 million and the lowest is $2.50 million. Pieris Pharmaceuticals posted sales of $13.26 million during the same quarter last year, which would indicate a negative year over year growth rate of 51.2%. The company is scheduled to report its next earnings results on Monday, May 10th.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full-year sales of $28.00 million for the current fiscal year, with estimates ranging from $24.41 million to $30.00 million. For the next financial year, analysts anticipate that the firm will post sales of $22.26 million, with estimates ranging from $11.88 million to $29.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Monday, March 29th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). Pieris Pharmaceuticals had a negative net margin of 59.11% and a negative return on equity of 55.20%.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Pieris Pharmaceuticals in a report on Tuesday, March 30th.

Institutional investors and hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC purchased a new position in shares of Pieris Pharmaceuticals during the fourth quarter valued at approximately $29,000. Principal Financial Group Inc. acquired a new position in Pieris Pharmaceuticals during the fourth quarter worth approximately $33,000. Navis Wealth Advisors LLC acquired a new position in Pieris Pharmaceuticals during the fourth quarter worth approximately $40,000. Squarepoint Ops LLC acquired a new position in Pieris Pharmaceuticals during the third quarter worth approximately $36,000. Finally, Jane Street Group LLC acquired a new position in Pieris Pharmaceuticals during the third quarter worth approximately $37,000. 57.46% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ PIRS opened at $2.64 on Thursday. Pieris Pharmaceuticals has a 12-month low of $1.95 and a 12-month high of $3.64. The company has a market capitalization of $147.76 million, a PE ratio of -4.98 and a beta of 1.40. The firm’s 50-day moving average is $2.67 and its two-hundred day moving average is $2.63.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

See Also: What does the Dogs of the Dow mean?

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.